

Announcement of Phase 2 trial results of Imarikiren (SCO-272)
at the 55th ERA-EDTA CONGRESS

SCOHIA PHARMA, Inc. will present results from the Phase 2 clinical trial of Imarikiren (development code: SCO-272) at the 55th ERA-EDTA CONGRESS, held from May 24 to 27, 2018 in Copenhagen, Denmark.

Session	Date, time and location	Title
Diabetes clinical Oral, Free communication	Saturday, May 26, 2018 8:00-9:30 C1-M3 conference room, BELLA CENTER COPENHAGEN	THE EFFICACY AND SAFETY OF IMARIKIREN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MICROALBUMINURIA: A RANDOMIZED, MULTI- CENTER, DOUBLEBLIND, PLACEBO CONTROLLED TRIAL

Contact for inquiries: info@scohia.com